$VIRX
Viracta Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016018570 Filed on May 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q1
Revenue $640.0K $670.0K $854.0K
YoY Change -25.06% -25.22% -57.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.300M $4.380M $5.110M
YoY Change -15.85% -27.96% 49.42%
% of Gross Profit
Research & Development $6.209M $7.630M $4.512M
YoY Change 37.61% 27.81% -40.25%
% of Gross Profit
Depreciation & Amortization $3.000K $10.00K $11.00K
YoY Change -72.73% 0.0% 120.0%
% of Gross Profit
Operating Expenses $10.50M $12.01M $9.623M
YoY Change 9.16% -0.33% -12.27%
Operating Profit -$9.864M -$8.769M
YoY Change 12.49% -2.28%
Interest Expense $298.0K -$230.0K $239.0K
YoY Change 24.69% -25.81% -56.31%
% of Operating Profit
Other Income/Expense, Net $76.00K $0.00 -$120.0K
YoY Change -163.33% -100.0% -97.62%
Pretax Income -$10.09M -$11.58M -$9.130M
YoY Change 10.51% 777.27% -37.34%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.09M -$11.58M -$9.128M
YoY Change 10.5% 777.27% -37.36%
Net Earnings / Revenue -1575.94% -1728.36% -1068.85%
Basic Earnings Per Share -$0.70 -$0.91 -$0.81
Diluted Earnings Per Share -$0.70 -$0.91 -$0.81
COMMON SHARES
Basic Shares Outstanding 14.44M 12.78M 11.27M
Diluted Shares Outstanding 14.44M 12.78M 11.27M

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.00M $46.40M $39.80M
YoY Change 0.5% 7.91% -43.71%
Cash & Equivalents $23.86M $26.89M $18.78M
Short-Term Investments $16.20M $19.50M $21.00M
Other Short-Term Assets $700.0K $600.0K $1.500M
YoY Change -53.33% -50.0% 36.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.70M $46.99M $41.30M
YoY Change -1.45% 6.3% -42.44%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $14.00K $0.00
YoY Change -66.67% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $14.00K $2.000K
YoY Change -100.0% -66.67% -97.3%
TOTAL ASSETS
Total Short-Term Assets $40.70M $46.99M $41.30M
Total Long-Term Assets $0.00 $14.00K $2.000K
Total Assets $40.70M $47.00M $41.30M
YoY Change -1.46% 6.23% -42.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $2.453M $2.121M
YoY Change 22.58% -22.79% 109.79%
Accrued Expenses $4.800M $6.300M $6.000M
YoY Change -20.0% -25.88% -10.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $7.800M $700.0K
YoY Change -100.0% -16.13% -92.47%
Total Short-Term Liabilities $9.775M $19.00M $15.92M
YoY Change -38.6% -31.86% -57.74%
LONG-TERM LIABILITIES
Long-Term Debt $11.70M $0.00 $6.900M
YoY Change 69.57% 2.99%
Other Long-Term Liabilities $0.00 $600.0K $1.700M
YoY Change -100.0% -76.92% 0.0%
Total Long-Term Liabilities $11.70M $600.0K $8.600M
YoY Change 36.05% -76.92% 2.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.775M $19.00M $15.92M
Total Long-Term Liabilities $11.70M $600.0K $8.600M
Total Liabilities $21.50M $19.60M $24.50M
YoY Change -12.24% -35.53% -46.85%
SHAREHOLDERS EQUITY
Retained Earnings -$569.5M -$531.8M
YoY Change 7.08% 7.6%
Common Stock $572.3M $548.6M
YoY Change 4.31% 5.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.27M $27.39M $16.79M
YoY Change
Total Liabilities & Shareholders Equity $40.73M $47.00M $41.30M
YoY Change -1.39% 6.22% -42.5%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q1
OPERATING ACTIVITIES
Net Income -$10.09M -$11.58M -$9.128M
YoY Change 10.5% 777.27% -37.36%
Depreciation, Depletion And Amortization $3.000K $10.00K $11.00K
YoY Change -72.73% 0.0% 120.0%
Cash From Operating Activities -$10.72M -$9.270M -$11.60M
YoY Change -7.59% 2.89% 1.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $3.400M -$5.850M -$210.0K
YoY Change -1719.05% -287.5% -105.41%
Cash From Investing Activities $3.400M -$5.850M -$210.0K
YoY Change -1719.05% -287.5% -105.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.290M 25.21M 8.410M
YoY Change -48.99% 246.77% -80.36%
NET CHANGE
Cash From Operating Activities -10.72M -9.270M -11.60M
Cash From Investing Activities 3.400M -5.850M -210.0K
Cash From Financing Activities 4.290M 25.21M 8.410M
Net Change In Cash -3.030M 10.09M -3.400M
YoY Change -10.88% 631.16% -109.65%
FREE CASH FLOW
Cash From Operating Activities -$10.72M -$9.270M -$11.60M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$9.270M -$11.60M
YoY Change 2.89% 1.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
16459000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
16459000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9775000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18999000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
610000
CY2016Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
11685000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
9000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
572257000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-569459000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
19268000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40728000
CY2016Q1 snss License And Other Revenue
LicenseAndOtherRevenue
640000
CY2016Q1 us-gaap Revenues
Revenues
640000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5111000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
10504000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9623000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9864000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
76000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8769000
CY2016Q1 us-gaap Interest Expense
InterestExpense
298000
CY2015Q1 us-gaap Interest Expense
InterestExpense
239000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10086000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9128000
CY2016Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
13000
CY2015Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
2000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10073000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9126000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86660000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67641000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
122000
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
44000
CY2015Q1 us-gaap Revenues
Revenues
854000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6209000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4512000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4295000
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
29431000
CY2015Q1 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
42000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4288000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8411000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3028000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3402000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22186000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18784000
CY2016Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
537000
CY2015Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
100000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1453000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1964000
CY2016Q1 snss Write Off Of Debt Discount Upon Note Repayment
WriteOffOfDebtDiscountUponNoteRepayment
27000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
89000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
143000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
128000
CY2016Q1 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
231000
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-677000
CY2016Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1163000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-610000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10715000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
43514000
CY2015Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
CY2016Q1 snss Payoff Notes Payable And Final Payment
PayoffNotesPayableAndFinalPayment
7153000
CY2016Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
229000
CY2015Q1 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
10011000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, debt instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2016Q1 us-gaap Notes Payable
NotesPayable
12500000
CY2016Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2016Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
40000000
CY2016Q1 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2016Q1 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35026000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22547000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
29434000
CY2015Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13276000
CY2015Q1 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
16155000
CY2015Q1 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
3000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13276000
CY2015Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16158000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
39347000
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19803000
CY2015Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
19555000
CY2015Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
11000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
19803000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
0
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q1 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
CY2016Q1 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2016Q1 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2016Q1 snss Proceeds To Be Received From Notes Payable
ProceedsToBeReceivedFromNotesPayable
2500000

Files In Submission

Name View Source Status
0001564590-16-018570-index-headers.html Edgar Link pending
0001564590-16-018570-index.html Edgar Link pending
0001564590-16-018570.txt Edgar Link pending
0001564590-16-018570-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gu4aa11omvrf000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20160331.htm Edgar Link pending
snss-20160331.xml Edgar Link completed
snss-20160331.xsd Edgar Link pending
snss-20160331_cal.xml Edgar Link unprocessable
snss-20160331_def.xml Edgar Link unprocessable
snss-20160331_lab.xml Edgar Link unprocessable
snss-20160331_pre.xml Edgar Link unprocessable
snss-ex101_325.htm Edgar Link pending
snss-ex103_327.htm Edgar Link pending
snss-ex104_328.htm Edgar Link pending
snss-ex105_329.htm Edgar Link pending
snss-ex106_330.htm Edgar Link pending
snss-ex107_331.htm Edgar Link pending
snss-ex311_285.htm Edgar Link pending
snss-ex312_286.htm Edgar Link pending
snss-ex321_287.htm Edgar Link pending